Drug Trial Radar · NCT00863538
Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Last checked: Nov 19, 2026Latest source record: Feb 3, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Planned (sponsor's estimate)
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD
Conditions
- Spinocerebellar Degeneration
Interventions
KPS-0373Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Scale for the assessment and rating of ataxia (SARA), ADL(Flow-FIM), Patient Improvement ImpressionTime frame: 12 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Japan
Hokkaido Region, Japan
Japan
Kansai Region, Japan
Japan
Kanto Region, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.